- Home
- LGVN vs PULM Comparison
LGVN vs PULM Comparison
Compare LGVN & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- PULM
- Stock Information
- Founded
- LGVN 2014
- PULM 2003
- Country
- LGVN United States
- PULM United States
- Employees
- LGVN N/A
- PULM N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- LGVN Health Care
- PULM Health Care
- Exchange
- LGVN Nasdaq
- PULM Nasdaq
- Market Cap
- LGVN 28.4M
- PULM 26.8M
- IPO Year
- LGVN 2021
- PULM N/A
- Fundamental
- Price
- LGVN $1.75
- PULM $6.47
- Analyst Decision
- LGVN Strong Buy
- PULM
- Analyst Count
- LGVN 3
- PULM 0
- Target Price
- LGVN $8.67
- PULM N/A
- AVG Volume (30 Days)
- LGVN 325.0K
- PULM 175.3K
- Earning Date
- LGVN 11-12-2024
- PULM 11-08-2024
- Dividend Yield
- LGVN N/A
- PULM N/A
- EPS Growth
- LGVN N/A
- PULM N/A
- EPS
- LGVN N/A
- PULM N/A
- Revenue
- LGVN $1,852,000.00
- PULM $10,005,000.00
- Revenue This Year
- LGVN $161.78
- PULM N/A
- Revenue Next Year
- LGVN $40.89
- PULM $1.00
- P/E Ratio
- LGVN N/A
- PULM N/A
- Revenue Growth
- LGVN 141.46
- PULM 47.05
- 52 Week Low
- LGVN $0.77
- PULM $1.55
- 52 Week High
- LGVN $21.30
- PULM $8.44
- Technical
- Relative Strength Index (RSI)
- LGVN 34.75
- PULM 64.99
- Support Level
- LGVN $1.80
- PULM $5.65
- Resistance Level
- LGVN $2.15
- PULM $6.54
- Average True Range (ATR)
- LGVN 0.12
- PULM 0.54
- MACD
- LGVN -0.02
- PULM -0.12
- Stochastic Oscillator
- LGVN 4.42
- PULM 42.86
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.